[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia; 2006 Mar;8(3):190-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
  • Breast cancer is the second most common cause of mortality after lung cancer.
  • Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated.
  • We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters.
  • The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%).
  • Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients.
  • In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001).
  • Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.
  • [MeSH-major] Antigens, CD / analysis. Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Antigens, CD274. Cell Line, Tumor / chemistry. Cell Line, Tumor / immunology. Cell Line, Tumor / pathology. Combined Modality Therapy. Epithelial Cells / metabolism. Estrogens. Female. Humans. Lymphatic Metastasis. Lymphocytes, Tumor-Infiltrating / metabolism. Mastectomy. Middle Aged. Neoadjuvant Therapy. Neoplasms, Hormone-Dependent / chemistry. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / immunology. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / surgery. Progesterone. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk Factors. Saudi Arabia / epidemiology. Tumor Burden. Tumor Escape / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 2004 Aug;18(9):1117-28; discussion 1131-2, 1137-8 [15471197.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2124-33 [15191948.001]
  • [Cites] Med Oncol. 1998 Dec;15(4):241-7 [9951687.001]
  • [Cites] Breast Cancer Res Treat. 1999 Apr;54(3):245-53 [10445423.001]
  • [Cites] Med Oncol. 1999 Jul;16(2):95-103 [10456657.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Oncologist. 2004;9(6):606-16 [15561805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9 [15569934.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):133-44 [15611321.001]
  • [Cites] Cancer Immunol Immunother. 2004 Dec;53(12):1146-52 [15185014.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):1089-96 [15705911.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1842-8 [15756008.001]
  • [Cites] J Neurosci. 2005 Mar 9;25(10):2537-46 [15758163.001]
  • [Cites] Annu Rev Immunol. 2005;23:515-48 [15771580.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):1-17 [15788636.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2947-53 [15837746.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):891-7 [15803183.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6265-70 [16272276.001]
  • [Cites] Immunol Lett. 2006 Feb 15;102(2):222-8 [16236366.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1345-6 [10581066.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1365-9 [10581077.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1027-34 [11015443.001]
  • [Cites] Br J Cancer. 2001 Jun 1;84(11):1433-6 [11384088.001]
  • [Cites] Nat Med. 2002 Aug;8(8):793-800 [12091876.001]
  • [Cites] Br Med Bull. 2002;62:149-62 [12176857.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 [12218188.001]
  • [Cites] Immunol Rev. 2002 Oct;188:97-113 [12445284.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1257-66 [12538684.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):545-53 [12548595.001]
  • [Cites] J Clin Invest. 2003 Feb;111(3):363-70 [12569162.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3637-44 [12646628.001]
  • [Cites] Nat Med. 2003 May;9(5):562-7 [12704383.001]
  • [Cites] J Mol Med (Berl). 2003 May;81(5):281-7 [12721664.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6501-5 [14559843.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7462-7 [14612546.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):328-39 [14993030.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 6;1704(1):11-35 [15238242.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5094-100 [15297412.001]
  • [Cites] J Neuroimmunol. 2004 Oct;155(1-2):172-82 [15342209.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(10):989-99 [9169643.001]
  • (PMID = 16611412.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone
  • [Other-IDs] NLM/ PMC1578520
  •  go-up   go-down


2. Afsar NA, Kulsoom B, Mateen A, Ahmed S, Tahseen M, Ahmed A: Breast cancer pattern and chemotherapy response--an institutional study in Pakistan. Asian Pac J Cancer Prev; 2010;11(3):825-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer pattern and chemotherapy response--an institutional study in Pakistan.
  • BACKGROUND: This study was planned to audit female breast cancers and their chemotherapy in a busy public sector institution.
  • RESULTS: A total of 3,431 female breast cancer patients presented during 2001-2008, half being <45 years, mostly suffering from infiltrating ductal carcinoma of breast.
  • Some 41.6% were either high grade or poorly differentiated.
  • The low grade tumors showed a two-fold likelihood of ER and PR positivity as compared to high grade lesions.
  • 5-Flourouracil, doxorubicin and cyclophosphamide (FAC) constituted the most common chemotherapy.
  • Overall, 33% developed myelotoxicity, more often if age ≥ 45 years (p=0.012), out of which 60% needed active correction.
  • CONCLUSIONS: Infiltrating ductal carcinoma of the breast is the most common type.
  • FAC is the most common chemotherapy.
  • Tendency for late diagnosis, metastatic disease, treatment failure as well as leukopenia especially in ≥ 45 years is present.
  • Failure to show leukopenia is suggestive of poor therapeutic outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039062.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


3. Chen P, Hu WM, Wang PH, Suen JH: Recurrent breast cancer presents as a single solid ovarian mass and ascites. Taiwan J Obstet Gynecol; 2006 Dec;45(4):356-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent breast cancer presents as a single solid ovarian mass and ascites.
  • However, aside from the primary origin, a metastatic lesion should be considered, since the ovary is frequently metastasized from cancers of other organs, such as the genital tract, gastrointestinal tract, and breast.
  • CASE REPORT: A 47-year-old woman with a history of right breast infiltrating lobular carcinoma, T3N0M0, grade 3, was treated with modified radical mastectomy and axillary lymph-node dissection in July 2001.
  • Therefore, she underwent palliative radiotherapy and various kinds of chemotherapy.
  • However, metastatic carcinoma of the ovary of breast origin was finally diagnosed.
  • [MeSH-major] Ascites / etiology. Breast Neoplasms / pathology. Carcinoma / secondary. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175500.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M: The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer; 2004 Feb;40(3):342-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
  • The aim of this study was to determine the chemosensitivity of infiltrating lobular breast carcinoma (ILC) in comparison with infiltrating ductal carcinoma (IDC).
  • Between 1987 and 1995, 457 patients with invasive T2>3 cm-T4 breast carcinomas were treated with primary chemotherapy (CT), surgery, radiation therapy.
  • Clinical response, the possibility of breast preservation, pathological response and survival were evaluated according to the histological type.
  • ILC was an independent predictor of a poor clinical response (P=0.02) and ineligibility for breast-conserving surgery after neoadjuvant chemotherapy (P=0.03).
  • Histological and biological factors predicting a poor response to CT (histological grade, ER, Ki67 and p53 status) were more frequent in ILC than in IDC patients.
  • Preoperative CT did not allow a high rate of conservative treatment for ILC and therefore the use of neoadjuvant CT for ILC patients should be questioned.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy / methods. Middle Aged. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14746851.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


5. Parshad R, Kapoor S, Gupta SD, Kumar A, Chattopadhyaya TK: Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol; 2002;41(4):362-5
Hazardous Substances Data Bank. FAMOTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study.
  • Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively.
  • Surgical specimens were evaluated objectively for tumor infiltrating lymphocytes in the center and in the periphery of the tumor along with evaluation of metastatic lymph nodes for reactive changes.
  • This response did not correlate with the stage, grade of tumor or menopausal status of patients in either group.
  • This study suggests that famotidine enhances tumor infiltrating lymphocytes in breast cancer and might have potential as an immunomodulator.
  • [MeSH-major] Breast Neoplasms / drug therapy. Famotidine / therapeutic use. Histamine H2 Antagonists / therapeutic use. Lymphocytes, Tumor-Infiltrating / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / immunology. Carcinoma, Lobular / pathology. Case-Control Studies. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12234028.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


6. Agrawal R: Synchronous dual malignancy: successfully treated cases. J Cancer Res Ther; 2007 Jul-Sep;3(3):153-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case report 1-A 70 year old female presented to us with lump in right breast for two years and bleeding per vaginum for two years.
  • Histopathology of cervix showed squamous cell carcinoma (large cell non keratinizing) and clinical stage was IIIB.
  • HPE mastectomy specimen showed infiltrating duct carcinoma and stage II.
  • Patient was treated with external beam radiotherapy for carcinoma cervix and breast simultaneously and chemotherapy as required.
  • HPE brain tissue showed astrocytoma grade II and HPE parotid tumour showed low grade muco-epidermoid carcinoma.
  • Thus it was concluded that patients responded well to treatment.
  • Treatment strategies in case of synchronous double malignancy depend on treating the malignancy that is more advanced first or sometimes both could be treated simultaneously.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Treatment Outcome


7. Ben Dhiab T, Bouzid T, Gamoudi A, Ben Hassouna J, Khomsi F, Boussen H, Benna F, El May A, Hechiche M, Rahal K: [Male breast cancer: about 123 cases collected at the Institute Salah-Azaiz of Tunis from 1979 to 1999]. Bull Cancer; 2005 Mar;92(3):281-5
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Male breast cancer: about 123 cases collected at the Institute Salah-Azaiz of Tunis from 1979 to 1999].
  • Male breast cancer is rare compared to its female counterpart representing less than 1% of cancer in men.
  • The objective of our retrospective study is to report the epidemiologic and clinical profile and to analyse the therapeutic results and prognostic factors in a Tunisian population collected during a period of 20 years at a single institution.
  • We collected from 1979 to 1999, all the histological confirmed male breast cancers treated at our institution.
  • We analyse the following data: age, clinical presentation and features, therapeutic protocol, results and prognostic factors.
  • 123 cases of male breast carcinoma were collected with a median age of 65 years.
  • Infiltrating ductal carcinoma represent 91% of all tumours.
  • The treatment consisted in a radical mastectomy in 93 cases (84%) followed by radiotherapy, chemotherapy and in many cases by hormonotherapy.
  • The presence of metastasis, nodal involvement, advanced disease, and grade affected survival.
  • Male breast cancer represent at our institution 1 % of the male cancers treated comparable to the literature data.
  • T4 tumours represent a higher rate, the treatment approach is the standard applicable in breast cancer; prognostic factors are the classical one like breast cancer in women.
  • [MeSH-major] Breast Neoplasms, Male / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820923.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Neonakis I, Mantadakis E, Gitti Z, Mitrouska I, Manidakis LG, Maraki S, Samonis G: Genital tuberculosis in a tamoxifen-treated postmenopausal woman with breast cancer and bloody vaginal discharge. Ann Clin Microbiol Antimicrob; 2006;5:20
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genital tuberculosis in a tamoxifen-treated postmenopausal woman with breast cancer and bloody vaginal discharge.
  • BACKGROUND: Female genital tuberculosis is an uncommon disease that is rarely diagnosed in developed countries.
  • CASE PRESENTATION: A 61-year-old postmenopausal woman who had undergone surgery and treated with adjuvant chemotherapy for infiltrating ductal carcinoma of the breast five years ago, presented with bloody vaginal discharge, fatigue, weight loss, and low grade fevers at night for two months.
  • Histological examination of the endometrium, done based on the suspicion of a second primary cancer due to the tamoxifen therapy, revealed a granulomatous reaction.
  • Liquid and solid mycobacterial cultures of the tissues were performed.
  • The patient was treated with a three-drug antituberculosis regimen for 9 months and recovered fully.
  • Early diagnosis is important and may prevent unnecessary invasive procedures for the patient.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Tamoxifen / adverse effects. Tuberculosis, Female Genital / drug therapy. Tuberculosis, Female Genital / etiology
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Middle Aged. Postmenopause. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberculosis.
  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Infect. 2002 Feb;78(1):62-3 [11872864.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3964-9 [12409359.001]
  • [Cites] J Obstet Gynaecol Res. 2002 Aug;28(4):203-10 [12452262.001]
  • [Cites] Trop Doct. 2003 Jan;33(1):7-11 [12568510.001]
  • [Cites] Commun Dis Public Health. 2003 Jun;6(2):133-8 [12889293.001]
  • [Cites] Int J Tuberc Lung Dis. 2003 Dec;7(12):1178-85 [14677893.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Mar;84(3):241-6 [15001372.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(4):277-9 [11408742.001]
  • [Cites] S Afr Med J. 1975 Jul 16;49(30):1228-32 [1154182.001]
  • [Cites] Am Rev Respir Dis. 1975 Dec;112(6):773-87 [812399.001]
  • [Cites] Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 2):974-7 [7468685.001]
  • [Cites] Health Bull (Edinb). 1982 Mar;40(2):87-91 [7085272.001]
  • [Cites] Int J Fertil. 1983;28(4):235-8 [6142016.001]
  • [Cites] Int J Tuberc Lung Dis. 1998 May;2(5):439 [9613645.001]
  • [Cites] Tuber Lung Dis. 1992 Dec;73(6):311-21 [1292709.001]
  • [Cites] S Afr Med J. 1992 Jan 4;81(1):12-5 [1729727.001]
  • [Cites] J Ky Med Assoc. 1985 Feb;83(2):75-6 [3973474.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Feb;72(2):165-9 [11166750.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Dec;75(3):269-72 [11728488.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 Oct;80(2):227-9 [9846674.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Sep;86(3):405-6 [15325867.001]
  • (PMID = 16948834.001).
  • [ISSN] 1476-0711
  • [Journal-full-title] Annals of clinical microbiology and antimicrobials
  • [ISO-abbreviation] Ann. Clin. Microbiol. Antimicrob.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ PMC1570363
  •  go-up   go-down


9. Geffen DB, Cagnano E, Tokar M, Ariad S, Koretz M: Ipsilateral breast carcinoma following treatment for primary breast lymphoma. Onkologie; 2007 Mar;30(3):134-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ipsilateral breast carcinoma following treatment for primary breast lymphoma.
  • BACKGROUND: The breast is an unusual site for primary non-Hodgkin's lymphoma.
  • Carcinoma in the same breast after treatment for lymphoma poses therapeutic challenges, but there is only 1 case report in Japanese, which describes this occurrence.
  • PATIENT AND METHODS: A 59-year-old woman was diagnosed with infiltrating ductal carcinoma of the breast after receiving doxorubicinand vincristine-based chemotherapy for ipsilateral primary large cell breast lymphoma.
  • The cancer was of high grade histology, with immunohistochemistry staining 3+ positive for HER2/neu.
  • Radiotherapy to the breast was administered, and a 1-year course of trastuzumab was planned.
  • CONCLUSION: Breast cancer can occur after breast lymphoma.
  • For primary breast lymphoma, cumulative doses of cardiotoxic and neurotoxic drugs should be limited to 3-4 cycles of chemotherapy, using treatment protocols for stage I-II large cell lymphoma.
  • Consolidation radiotherapy should be considered at a dose curative for microscopic breast cancer.
  • [MeSH-major] Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / therapy. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Mastectomy, Segmental. Middle Aged. Radiotherapy, Adjuvant. Receptor, ErbB-2 / analysis. Retreatment

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341900.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Kaufmann P, Dauphine CE, Vargas MP, Burla ML, Isaac NM, Gonzalez KD, Rosing D, Vargas HI: Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery. Am Surg; 2006 Oct;72(10):935-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
  • Neoadjuvant chemotherapy (NC) in patients with breast cancer results in high response rates and has been used with the purpose of reducing tumor size and achieving breast conservation (BC) in individuals who initially require mastectomy.
  • We conducted a cohort study of women with invasive breast cancer who required mastectomy but desired BC surgery.
  • Tumors were predominantly infiltrating ductal carcinoma (83.3%) and high grade (62.2%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Mastectomy. Mastectomy, Segmental. Neoadjuvant Therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biomarkers, Tumor / analysis. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Cohort Studies. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Remission Induction. Retrospective Studies. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058739.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Zunzunegui RG, Chung MA, Oruwari J, Golding D, Marchant DJ, Cady B: Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease? Arch Surg; 2003 May;138(5):537-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease?
  • HYPOTHESIS: Women with breast cancer who have casting-type microcalcifications associated with multifocal invasion and extensive ductal carcinoma in situ (DCIS) form a subset of patients with a poor prognosis.
  • DESIGN: Women with casting-type microcalcifications, multifocal invasion, and extensive DCIS were identified from our tumor board registry.
  • Mammographic features, tumor characteristics, treatment, and survival rates were evaluated.
  • Invasive tumors were limited to 14 mm or smaller.
  • SETTING: University medical teaching hospital and breast cancer specialty clinic.
  • RESULTS: Of the 984 patients with breast cancer treated at our center, 15 patients were identified who had extensive casting-type calcifications and DCIS.
  • Twelve of these patients also had multifocal invasive breast cancer.
  • All had casting-type microcalcifications occupying more than 1 breast quadrant.
  • All but 1 patient had extensive grade 3 DCIS.
  • Invasive tumors were negative for estrogen receptor and progesterone receptor expression in half of the patients, and 60% were positive for the HER-2-neu receptor.
  • Positive axillary lymph nodes were found in 33% of patients, and 75% received adjuvant chemotherapy.
  • Of the 3 patients who had DCIS without invasion, 1 experienced a recurrence with infiltrating ductal carcinoma.
  • CONCLUSIONS: In women with small multifocal breast cancers with extensive casting calcifications and DCIS, the incidence of positive lymph nodes was 33%, with a tendency for poor tumor markers.
  • These women appear to be at substantial risk for systemic disease; lymph node sampling and adjuvant systemic therapy are recommended.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12742959.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Prasad ML, Osborne MP, Giri DD, Hoda SA: Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol; 2000 Mar;24(3):422-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases.
  • Clinicopathologic data on microinvasive carcinoma of the breast (MICB) as defined by the 1997 TNM criteria (T1mic < or = 1 mm) is scarce.
  • Histologic slides of 109 cases from 1993 through 1997, in which microinvasion was either suspected or diagnosed initially, were reviewed.
  • MICB was ductal in 18 patients, including one tubular carcinoma, and was lobular in three patients.
  • The mean number of invasive foci was two per patient (range, one to seven foci).
  • The accompanying duct carcinoma in situ had high-grade nuclei and necrosis in 16 of 18 patients (89%), 13 of which (72%) were comedo-type.
  • Eleven patients underwent mastectomy, nine received radiation therapy, one received chemotherapy, and two underwent lumpectomy only.
  • One patient had a chest wall recurrence of infiltrating duct carcinoma and another recurred with duct carcinoma in situ.
  • [MeSH-major] Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10716157.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Hajduk M: Topoisomerase II alpha--a fundamental prognostic factor in breast carcinoma. Pol J Pathol; 2009;60(2):67-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II alpha--a fundamental prognostic factor in breast carcinoma.
  • The objective of the present investigation was the assessment of topoisomerase II alpha (TOP2A) expression in patients with infiltrating breast carcinoma, as a prognostic factor in correlation with other recognized prognosticators and patient survival.
  • The study was carried out in 151 patients treated by mastectomy and lymph node excision followed by adjuvant chemotherapy.
  • The material was evaluated histopathologically according to the pTNM system, taking into consideration such parameters as grade of malignancy (G); the ER, PR as well as HER2 and TOP2A receptors status--all of them were assessed immunohistochemically.
  • TOP2A was expressed with varying intensity in the majority of infiltrating ductal carcinomas studied, more frequently in large T3 and T4, grade G2 and G3 tumours, in patients with extensive metastases to regional N2 and N3 lymph nodes, a positive HER2 and negative ER and PR status.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Female. Humans. Immunoenzyme Techniques. Lymph Node Excision. Mastectomy. Middle Aged. Prognosis. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886180.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


14. Tsai KB, Hou MF, Lin HJ, Chai CY, Liu CS, Huang TJ: Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer. Kaohsiung J Med Sci; 2001 Feb;17(2):64-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
  • The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers.
  • Moreover, it is an entry criterion in the assessment of patients for whom Herceptin (Trastuzumab) treatment is considered.
  • The overexpression rate of HER-2/neu oncoprotein has been identified in 10% to 40% of human breast cancers.
  • In Taiwan, a higher grade of pathobiologic characteristics of familial breast cancer was also noted than that found in the non-familial group.
  • It is worthwhile to evaluate whether the overexpression is more frequent in familial breast cancers.
  • Fifty-six familial and 111 non-familial breast cancers were studied between 1990 and 1999 to assess both the overexpression of HER-2/neu oncoprotein immunohistochemically and the correlation with the histological type, grade and stage of breast carcinoma.
  • The overexpression rate is higher in the familial breast cancer group (50.0%) when compared with non-familial breast cancer group (36.9%), which did not prove to be statistically significant (P = 0.1068).
  • However, when the infiltrating ductal carcinomas of both groups are compared, it is statistically significant (52.3% vs. 33.7%, P = 0.0429).
  • Overexpression correlated with node status and histological grade of infiltrating ductal carcinomas in non-familial and overall breast cancers.
  • It also correlated with nuclear pleomorphism and mitotic counts, but not tubule formation or tumor size.
  • All 3 cases of Paget's disease revealed overexpression, whereas all 12 cases of mucinous and one case of metaplastic carcinoma and one case of medullary carcinoma were negative.
  • A case of infiltrating ductal carcinoma combined with intraductal carcinoma revealed heterogeneous staining in the component of ductal carcinoma in situ, while the invasive component did not.
  • This suggests that overexpression decreases within individual tumors as they evolve from in situ to invasive lesioins.
  • The HER-2/neu may imply a different role in intraductal carcinoma, Paget's disease and invasive duct carcinoma.
  • Although the overexpression rate of HER-2/neu oncoprotein of familial breast cancer was not significantly higher than that of the non-familial group, it is appropriate to evaluate the rate of HER-2/neu overexpression according to the histological type of breast cancers from familial breast cancer and non-familial breast cancer.
  • [MeSH-major] Breast Neoplasms / chemistry. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11416960.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


15. Gil Gil MJ, Barnadas A, Cirera L, Tusquets I, Muñoz M, Arcusa A, Prieto L, Moreno A, Graupera J, Margeli M: Primary hormonal therapy with exemestane in patients with breast tumors &gt;3 cm in diameter: Results of a Spanish multicenter phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):603

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial.
  • : 603 Background: Primary hormonal therapies have demonstrated great activity in elderly women with locally advanced and hormone-dependent breast tumors.
  • The primary aim of this study was to analyze the efficacy of exemestane as a neoadjuvant treatment.
  • Inclusion criteria were histologic diagnosis of infiltrating breast carcinoma, no metastatic disease, tumor >3 cm (T2, T3, T4a-b), >50% ER+, and no previous hormonal treatment/chemotherapy.
  • At baseline, all p were considered noneligible for breast-conserving surgery.
  • TREATMENT: oral exemestane 25 mg/d for 6 months.
  • Response was estimated by mammography and breast ultrasound every 2 months (RECIST criteria).
  • Secondary endpoints were rate of breast-conserving surgery, time to progression, duration of response, and toxicity.
  • To date, 50 p have been evaluated for response and 5 remain under treatment.
  • RESULTS: Patient characteristics: median age 77 (67-88); tumor stage: T2: 25, T3: 7 and T4a-b: 23; nodal status: N0: 30, N1: 20 and N2: 5; tumor grade I: 3, II: 24, III: 6 and unknown: 22.
  • Median time to surgery: 7 months.
  • Surgery type: conservative 21 p, mastectomy 17 p, no operation 12 p (various reasons).
  • Pathologic complete response was observed in the breast and axilla in 3 p; partial pathologic remission was seen in 14 p.
  • Grade I-II toxicity: hot flushes, nausea, dizziness, and pain.
  • CONCLUSIONS: Exemestane was found to be a well-tolerated and effective neoadjuvant treatment in elderly patients with a breast cancer tumor >3 cm in diameter.
  • No severe treatment-related adverse events were detected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016638.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Székely B, Langmár Z, Somlai K, Szentmártoni G, Szalay K, Korompay A, Szász AM, Kulka J, Bánhidy F, Dank M: [Treatment of pregnancy associated breast cancer]. Orv Hetil; 2010 Aug 8;151(32):1299-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pregnancy associated breast cancer].
  • Pregnancy-associated breast cancer (PABC) is defined as cancer of the breast diagnosed during pregnancy and up to 1 year postpartum.
  • Young patients with PABC do not have worse prognosis compared with those with non-PABC; however, pregnancy can contribute to a delay in breast cancer diagnosis, evaluation, and treatment.
  • Primary care physicians and gynecologists should be careful in the thorough workup of breast symptoms in the pregnant population to expedite diagnosis and allow multidisciplinary treatment as early as possible following the established diagnosis.
  • Authors report a case of a 30-year-old pregnant woman, who detected inflammatory signs of her right breast and a palpable axillary mass at the 21st week of gestation.
  • Therefore fine needle aspiration biopsy of the axillary lump was performed, with the result of unequivocal diagnosis of metastatic invasive carcinoma.
  • The patient was referred to the multidisciplinary tumor board of our Department at the 27st week of gestation with the symptoms of inflammatory breast cancer, palpable right axillary and supraclavicular lymph nodes.
  • Core biopsy showed an ER and PR negative, Her-2 positive, grade 3, infiltrating ductal carcinoma of the breast.
  • After multidisciplinary team consultation the patient declined any kind of therapy during her pregnancy.
  • After 6 cycles of chemotherapy (docetaxel-doxorubicin-cycclophosphamid) the patient underwent right mastectomy and axillary lymph node dissection.
  • After radiotherapy, trastuzumab medication was initiated.
  • Had the patient accepted chemotherapy, the damage of the newborn baby would have been avoidable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Choice Behavior. Female. Humans. Inflammation. Interdisciplinary Communication. Lymphatic Metastasis. Mastectomy / methods. Neoadjuvant Therapy / methods. Patient Participation. Pregnancy. Radiotherapy, Adjuvant. Treatment Outcome


17. López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA: Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep; 2008 Dec;20(6):1369-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
  • Primary pure neuroendocrine breast carcinomas (NEBC) have been considered special features within conventional breast carcinomas until recently.
  • In 2003, the World Health Organization (WHO) classification of breast tumors definitely established that the immunohistochemical expression of NE markers in more than 50% of the tumor cell population is the unique requisite for NEBC diagnosis.
  • Herein, we sought to determine the incidence, the clinico-pathological features and the immunohistochemical profile of NEBC in a large series of 1368 infiltrating breast tumors collected from 1989 to 2008 in our institution (Dr Josep Trueta University Hospital, Girona, Catalonia).
  • All the NECB were grade 2 ductal carcinoma infiltrating (DCI) with tumor sizes ranging from 7 to 55 mm.
  • All the patients bearing NECB received hormone therapy and 4 of them underwent radiotherapy and/or chemotherapy.
  • These findings revealed that: a) Pure solid NEBC do not significantly differ from other breast carcinomas in terms of general clinical features;.
  • Although it remains to be elucidated whether the good prognosis of NEBC relates to the intrinsic nature of the tumor and/or to a high rate of treatment responses, their immunohistochemical profile strongly suggest that NEBC belong to the Luminal A BC subtype.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / immunology. Carcinoma / epidemiology. Carcinoma / immunology. Immunohistochemistry / methods. Neuroendocrine Tumors / epidemiology. Neuroendocrine Tumors / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Cell Differentiation. Chemotherapy, Adjuvant / methods. Female. Humans. Incidence. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020716.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


18. Geylan-Su YS, Isgör B, Coban T, Kapucuoglu N, Aydintug S, Iscan M, Iscan M, Güray T: Comparison of NAT1, NAT2 and GSTT2-2 activities in normal and neoplastic human breast tissues. Neoplasma; 2006;53(1):73-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of NAT1, NAT2 and GSTT2-2 activities in normal and neoplastic human breast tissues.
  • In this study, arylamine N-acetyltransferases, NATs (E.C.2.3.1.5) and glutathione-S-transferase-T2-2, GSTT2-2 (E.C.2.5.1.18) enzyme activities in the breast tumor and surrounding tumor-free tissues of 22 female breast cancer patients with infiltrating ductal carcinoma were measured.
  • The possible impacts of grade of malignancy, chemotherapy treatment, estrogen receptor status and menopausal status on all enzyme activities were evaluated.
  • The results showed that, both NAT2 and GSTT2-2 display significant differences between tumor and tumor-free breast tissues, while no difference was observed in NAT1.
  • Grade of malignancy seems to be positively associated with NAT1 and negatively associated with GSTT2-2.
  • Though, both NAT2 and GSTT2-2 have increased mean tumor activities, the grade of malignancy, chemotherapy status, menopausal status or estrogen receptor status are not correlated statistically.
  • [MeSH-major] Arylamine N-Acetyltransferase / metabolism. Breast / enzymology. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Glutathione Transferase / metabolism. Isoenzymes / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416017.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / GSTT2 protein, human; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


19. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordière A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A: Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (&lt;40 years) women treated with breast conserving surgery first. Radiother Oncol; 2007 Mar;82(3):272-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first.
  • PURPOSE: To ascertain the loco-regional recurrence (LRR) rate and its major prognostic factors in patients younger than 40 and to determine the influence of age on the features of breast cancer and its treatment in two age groups: 35 years and [36-39] years.
  • METHODS AND MATERIALS: Between 1985 and 1995, 209 premenopausal women, younger than 40, were treated for early breast cancers with primary breast conserving surgery followed by radiotherapy+/-chemotherapy.
  • RESULTS: LRR rate was 38% at 10 years, contralateral breast cancer rate 12%.
  • The annual risk of local recurrence peaked between 2 and 3 years after the initial diagnosis and returned to the level of contra-lateral breast cancer at 10 years.
  • The younger population had infiltrating carcinomas that were significantly more commonly ductal, less commonly lobular, and of higher grade - they received chemotherapy more often.
  • CONCLUSION: Using conventional methods we could find no explanation as to why age remained the most important prognostic factor for breast cancer LRR.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Age Factors. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2008 Feb;86(2):286-7; author reply 287-8 [17963905.001]
  • [ErratumIn] Radiother Oncol. 2007 May;83(2):215
  • (PMID = 17287037.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


20. Perera F, Yu E, Engel J, Holliday R, Scott L, Chisela F, Venkatesan V: Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up. Int J Radiat Oncol Biol Phys; 2003 Dec 1;57(5):1239-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up.
  • PURPOSE: In this pilot study of high-dose-rate brachytherapy to the lumpectomy site as the sole radiation, ipsilateral and contralateral breast recurrences are documented with specific attention to the location of recurrence relative to the lumpectomy site.
  • METHODS: Between March 1992 and January 1996, 39 patients with T1 (32 patients) and T2 breast cancers received 37.2 Gy in 10 fractions (b.i.d.) over 1 week prescribed to a volume encompassing the surgical clips.
  • Thirteen received adjuvant tamoxifen, and 4 received chemotherapy.
  • Follow-up included annual bilateral mammograms and clinical breast examination every 3 to 6 months.
  • The latter group and 7 of the former group had surgical clips marking the lumpectomy site, which allowed estimates of the distance of any ipsilateral breast recurrence from the lumpectomy site, using the mediolateral and cranio-caudad mammographic views.
  • The 5-year actuarial rate of ipsilateral breast recurrence was 16.2%.
  • One of the 2 patients had a 1-mm microscopic margin at initial diagnosis; the recurrence was a 3.5-mm microscopic focus of duct carcinoma in situ.
  • The other patient had a 1.5-cm, high-grade infiltrating mammary carcinoma with no residual at wider resection at first diagnosis; the 5-mm invasive recurrence was also of high grade.
  • Four women developed invasive recurrences at least 1.6 cm or more from the lumpectomy site (out-of-field recurrences).
  • All ipsilateral breast recurrences were salvaged by mastectomy (4 patients) or by repeat lumpectomy (2 patients) and whole-breast radiation.
  • There were two contralateral breast recurrences at intervals of 34 and 36 months; 1 of these patients also had a multifocal, ipsilateral recurrence at 58 months, as previously described.
  • Among patients with any breast recurrence, 1 patient had a family history of prostate cancer; there was no family history of breast or ovarian cancer.
  • Of 17 patients who received adjuvant systemic therapy, only 1 had a breast recurrence.
  • CONCLUSIONS: In this pilot study, breast recurrences outside of the lumpectomy site were the predominant pattern of recurrence.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Chemotherapy, Adjuvant. Dose Fractionation. Female. Follow-Up Studies. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Pilot Projects. Salvage Therapy. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1214-6 [14630253.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1210-3 [14630252.001]
  • (PMID = 14630257.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Borg M, Wilkinson D, Humeniuk V, Norman J: Successful treatment of radiation induced breast ulcer with hyperbaric oxygen. Breast; 2001 Aug;10(4):336-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of radiation induced breast ulcer with hyperbaric oxygen.
  • The purpose of this report was to investigate the efficacy of hyperbaric oxygen treatment in the management of a persisting radiation induced ulcer following standard breast irradiation.
  • A 57-year-old Caucasian patient was referred following partial mastectomy and axillary node clearance for a T2N0 grade 3 infiltrating ductal carcinoma of the left breast.
  • She received 45 Gy in 25 fractions at 1.8 Gy per fraction to the isocentre to the whole breast using tangential fields and 4 MV photons, in conjunction with intravenous chemotherapy (cyclophosphamide, methotrexate and 5 fluorouracil).
  • Treatment was interrupted for 3.5 weeks because of a grade 4 skin and subcutaneous reaction.
  • Treatment resumed to the tumour bed alone.
  • Chemotherapy was abandoned.
  • The tumour bed received 14 Gy in 7 fractions at 2 Gy per fraction prescribed to the 100% using 10 MeV electrons and a direct field, completing treatment on 7 July 1998.
  • The radiation induced a painful 8x4 cm ulcer which persisted in spite of rigorous treatment including Gentian Violet, Silvazine Cream, Duoderm and antibiotics.
  • The patient received 30 hyperbaric treatments, six times a week, completing treatment on 15 December 1998.
  • The breast ulcer showed a response to treatment with early healing after 7-8 days and clinical evidence of re-epithelization.
  • At completion of 30 treatments the patient was left with a small shallow faintly discharging multilocular 3-4 cm ulcer.
  • The patient has been symptom free since completion of treatment.
  • This report highlights the efficacy of hyperbaric oxygen therapy in the management of persisting radiation-induced ulcers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965605.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


22. Susnjar S, Kezić I, Nesković-Konstantinović Z, Gavrilović D, Nikolić-Vukosavljević D: The influence of steroid receptors status on disease outcome in early breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy. J BUON; 2005 Jul-Sep;10(3):385-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of steroid receptors status on disease outcome in early breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy.
  • PURPOSE: To assess the influence of steroid receptors (SR) status on disease outcome of early breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
  • PATIENTS AND METHODS: Sixty-six node-negative patients with grade 3 invasive breast carcinoma and 95 patients with 1-3 involved axillary lymph nodes regardless of tumor grade received adjuvant CMF chemotherapy.
  • However, positive lymph nodes were the only significant predictor of disease progression among patients receiving CMF therapy (Likelihood Ratio test, p <0.001).
  • Women under 40 bearing SR-positive breast cancer had a trend toward worse DFS (log rank test, p=0.054) compared to older SR-positive premenopausal women.
  • CONCLUSION: We can not unequivocally reveal the influence of SR status on disease outcome in early breast cancer patients treated with adjuvant CMF, although SR-positive patients in the node-negative group were shown to have worse DFS in comparison to SR-negative ones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357194.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Paciucci PA, Raptis G, Bleiweiss I, Weltz C, Lehrer D, Gurry R: Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs; 2002 Sep;13(8):791-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
  • Neo-adjuvant, dose-dense docetaxel, 100 mg/m(2) every 2 weeks x 4 cycles, was administered to 12 patients with locally advance breast cancer (LABC) (10 stage IIIa and three stage IIIb).
  • Filgrastim [granulocyte colony stimulating factor (G-CSF)] was started 1 day after chemotherapy and was given for 6 days.
  • The median age was 45 (range 34-73) and pre-treatment pathology revealed poorly differentiated infiltrating duct carcinoma in 11 and infiltrating lobular cancer in one, with positive ER/PR status in five.
  • Three patients (of whom two with stage IIIb) had progressive disease and went on to receive neo-adjuvant therapy with AC.
  • There was one instance of grade 3 hematologic toxicity (neutropenic fever in one G-CSF non-compliant patient).
  • There were two instances of grade 3 extra-hematologic toxicity: one patient had severe pain and one had treatment-related fatigue.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / administration & dosage. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Filgrastim. Humans. Middle Aged. Neoadjuvant Therapy. Recombinant Proteins

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12394262.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


24. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K: Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol; 2007 Jan;14(1):166-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base.
  • BACKGROUND: Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components.
  • With few published reports, we hypothesized that MBC may have markedly different characteristics at presentation than typical infiltrating ductal carcinoma (IDC) and may be managed differently.
  • METHODS: Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson chi(2) test.
  • The group with MBC was older (mean age, 61.1 vs. 59.7 years; P = .001), had a significantly increased proportion of African American (14.1%, 126 of 892, vs. 10.2%, 25,900 of 255,164; odds ratio [OR], 1.455, P = .001) and Hispanic patients (5.5%, 49 of 892 vs. 3.9%, 9,947 of 255,164; OR, 1.817, P = .001), had fewer T1 tumors (29.5% vs. 65.2%), more N0 tumors (78.1% vs. 65.7%, OR, .5, P = .001), more poorly or undifferentiated tumors (67.8% vs. 38.8%), and fewer estrogen receptor-positive tumors (11.3% vs. 74.1%, OR, 22.4, P = .001) than the IDC group.
  • Patients with MBC were treated with breast-conserving surgery less frequently than patients with IDC (38.5% vs. 55.8%, OR, 2.0, P = .001) because of the larger tumor size.
  • Chemotherapy was used more often for patients with MBC (53.4% vs. 42.1%, OR, 1.6, P = .001) because of more advanced AJCC stage.
  • CONCLUSIONS: MBC is a rare tumor with different characteristics than IDC: it presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity.
  • Patients with MBC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation, but are being treated by the same principles as IDC.
  • Follow-up will determine the long-term results of the current treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066230.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement